Funding for this research was provided by:
National Research Council
Received: 13 May 2022
Accepted: 29 June 2022
First Online: 7 July 2022
: Approval was obtained from the Medical Research Ethics Committee of National Research Centre Number (MREC-NRC): 19246. The procedures used in this study adhere to the standards of the Declaration of NRC.
: Not applicable.
: Animal models should be used before preclinical studies on human volunteers to determine the exact dose of RE nanoparticles. Also, the most effective administration route must be stated. These studies will allow measuring plasma level of bioactive ingredients of RE nanoparticles after local application on mucosa. This will help revealing any side effects with prolonged use of local RE nanoparticles.
: The authors have no competing interests to declare that are relevant to the content of this article.